RNAi screening uncovers DHX9 as a modifier of ABT-737 resistance in an Em-myc/BCL-2 mouse model

Blood

Volumn 121, Issue 17, 2013, Pages 3402-3412

  Mills, John R ^a   Malina, Abba ^a   Lee, Teresa ^a   Paola, Domenic Di ^a   Larsson, Ola ^b   Miething, Cornelius ^c,d   Grosse, Frank ^e   Tang, Hengli ^f   Zannis Hadjopoulos, Maria ^a,g,h   Lowe, Scott W ^c,d,i   Pelletier, Jerry ^a,g,h,j  

^a MCGILL UNIVERSITY   (Canada)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Cold Spring Harbor Laboratories ^*  (Canada)

^d Memorial Sloan Kettering Cancer Center   (Canada)

^e FRITZ LIPMANN INSTITUTE   (Germany)

^f FLORIDA STATE UNIVERSITY   (United States)

^g Department of Oncology ^*  (United Arab Emirates)

^h MCGILL UNIVERSITY   (Canada)

ⁱ Howard Hughes Medical Institute   (Canada)

^j MCGILL UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; DHX9 PROTEIN; DNA HELICASE; MYC PROTEIN; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P53; RNA HELICASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ABT-737; BIPHENYL DERIVATIVE; CDKN2A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEAD BOX PROTEIN; DHX9 PROTEIN, MOUSE; MYC PROTEIN, MOUSE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITROPHENOL; PIPERAZINE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CONTROLLED STUDY; DNA RNA HYBRIDIZATION; DRUG RESISTANCE; DRUG SENSITIVITY; ENHANCER REGION; HUMAN; HUMAN CELL; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; ANIMAL; CELL CYCLE; DISEASE MODEL; DRUG ANTAGONISM; GENETICS; LYMPHOMA; METABOLISM; MODIFIER GENE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BIPHENYL COMPOUNDS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DEAD-BOX RNA HELICASES; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GENES, MODIFIER; HUMANS; LYMPHOMA; MICE; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE; SULFONAMIDES;

MLCS; MLOWN;

EID: 84879158290     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-434365     Document Type: Article

References (49)

1. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11(9):621-632.
2. Llambi F, Moldoveanu T, Tait SW, et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell. 2011; 44(4):517-531.
3. Happo L, Cragg MS, Phipson B, et al. Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood. 2010; 116(24):5256-5267.
4. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008;7(12):989-1000.
5. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of BCL-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-681.
6. Kutuk O, Letai A. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res. 2008;68(19):7985-7994.
7. Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A. The BCL-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res. 2007;13(23):7191-7198.
8. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective BCL-2 proteins and efficiently induces apoptosis via Bak/Bax if MCL-1 is neutralized. Cancer Cell. 2006;10(5): 389-399.
9. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, Cohen GM. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2009; 113(18):4403-4413.
10. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood. 2010;115(16): 3304-3313.
11. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283): 899-905.
12. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318(6046): 533-538.
13. Schmitt CA, Lowe SW. Apoptosis and chemoresistance in transgenic cancer models. J Mol Med (Berl). 2002;80(3):137-146.
14. Darzynkiewicz Z, Juan G. Analysis of DNA content and BrdU incorporation. Curr Protoc Cytom. 2001;Chapter 7(7):7.7.1-7.7.9.
15. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K, Korsmeyer SJ. Obligate role of antiapoptotic MCL-1 in the survival of hematopoietic stem cells. Science. 2005;307(5712):1101-1104.
16. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003;426(6967): 671-676.
17. Kelly PN, Puthalakath H, Adams JM, Strasser A. Endogenous BCL-2 is not required for the development of Emu-myc-induced B-cell lymphoma. Blood. 2007;109(11):4907-4913.
18. Mason KD, Vandenberg CJ, Scott CL, Wei AH, Cory S, Huang DC, Roberts AW. In vivo efficacy of the BCL-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci USA. 2008;105(46):17961-17966.
19. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13(20): 2658-2669.
20. Mills JR, Hippo Y, Robert F, et al. mTORC1 promotes survival through translational control of MCL-1. Proc Natl Acad Sci USA. 2008;105(31): 10853-10858.
21. Robert F, Carrier M, Rawe S, Chen S, Lowe S, Pelletier J. Altering chemosensitivity by modulating translation elongation. PLoS ONE. 2009;4(5):e5428.
22. Wendel HG, Silva RL, Malina A, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007; 21(24):3232-3237.
23. Schlabach MR, Luo J, Solimini NL, et al. Cancer proliferation gene discovery through functional genomics. Science. 2008;319(5863):620-624.
24. Brady CA, Jiang D, Mello SS, et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell. 2011;145(4):571-583.
25. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA. 2006;103(6):1888-1893.
26. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival BCL-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17(3):393-403.
27. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117(1):112-121.
28. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4(2):199-207.
29. Dominguez-Sola D, Ying CY, Grandori C, et al. Non-transcriptional control of DNA replication by c-Myc. Nature. 2007;448(7152):445-451.
30. Robinson K, Asawachaicharn N, Galloway DA, Grandori C. c-Myc accelerates S-phase and requires WRN to avoid replication stress. PLoS ONE. 2009;4(6):e5951.
31. Ferrao PT, Bukczynska EP, Johnstone RW, McArthur GA. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene. 2011;31(13):1661-1672.
32. Chow KC, Ross WE. Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Mol Cell Biol. 1987;7(9):3119-3123.
33. Gómez M, Brockdorff N. Heterochromatin on the inactive X chromosome delays replication timing without affecting origin usage. Proc Natl Acad Sci USA. 2004;101(18):6923-6928.
34. Sibani S, Rampakakis E, Di Paola D, Zannis-Hadjopoulos M. Fine mapping and functional activity of the adenosine deaminase origin in murine embryonic fibroblasts. J Cell Biochem. 2008;104(3):773-784.
35. Fuller-Pace FV. DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation. Nucleic Acids Res. 2006;34(15):4206-4215.
36. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science. 2003;302(5647):1036-1038.
37. Michalak EM, Jansen ES, Happo L, et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ. 2009;16(5):684-696.
38. Wiegmans AP, Alsop AE, Bots M, et al. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Res. 2011;71(10): 3603-3615.
39. Höglund A, Nilsson LM, Muralidharan SV, et al. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin Cancer Res. 2011;17(22):7067-7079.
40. Cole KA, Huggins J, Laquaglia M, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci USA. 2011; 108(8):3336-3341.
41. Moser R, Toyoshima M, Robinson K, et al. MYC-driven tumorigenesis is inhibited by WRN syndrome gene deficiency. Mol Cancer Res. 2012;10(4):535-545.
42. Grandori C, Wu KJ, Fernandez P, et al. Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev. 2003;17(13): 1569-1574.
43. Lachapelle S, Gagné JP, Garand C, et al. Proteome-wide identification of WRN-interacting proteins in untreated and nuclease-treated samples. J Proteome Res. 2011;10(3): 1216-1227.
44. Friedemann J, Grosse F, Zhang S. Nuclear DNA helicase II (RNA helicase A) interacts with Werner syndrome helicase and stimulates its exonuclease activity. J Biol Chem. 2005;280(35): 31303-31313.
45. Chakraborty P, Grosse F. WRN helicase unwinds Okazaki fragment-like hybrids in a reaction stimulated by the human DHX9 helicase. Nucleic Acids Res. 2010;38(14):4722-4730.
46. Ammazzalorso F, Pirzio LM, Bignami M, Franchitto A, Pichierri P. ATR and ATM differently regulate WRN to prevent DSBs at stalled replication forks and promote replication fork recovery. EMBO J. 2010;29(18):3156-3169.
47. Jain A, Bacolla A, Chakraborty P, Grosse F, Vasquez KM. Human DHX9 helicase unwinds triple-helical DNA structures. Biochemistry. 2010;49(33): 6992-6999.
48. Schlegel BP, Starita LM, Parvin JD. Overexpression of a protein fragment of RNA helicase A causes inhibition of endogenous BRCA1 function and defects in ploidy and cytokinesis in mammary epithelial cells. Oncogene. 2003;22(7): 983-991.
49. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11): 2273-2279.